Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Biomarkers for Prostate and Bladder Cancer

Biomarkers for Prostate and Bladder Cancer

114
Liu, Alvin Y.University of Washington

No involved investigator sites defined.

CD90, AGR2, CEACAM5
Genomics
Proteomics
Prostate and Urologic Cancers Research Group

CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, CD49a+ stromal and CD31+ endothelial was carried out to identify candidates: CD90, AGR2, BCMP11, CEACAM5, CRISP3. Quantitative protomics was applied to measure these proteins in urine samples.

Sort cancer cells from tumor specimens Determine gene expression (transcriptome) by Affymetrix DNA arrays Dataset analysis to identify cancer up-regulated genes encoding secreted or extracellular proteins Proteomic analysis (mass spectrometry, Western blotting) to validate increased cancer expression
Genomics and proteomics. DNA microarray analysis of sorted cell types to identify cancer-specific genes encoding secreted/extracellular proteins. Mass spectrometry-based proteomics to measure protin levels in case vs. control urine samples.
Data analysis was done to evaluate data quality of Affymetrix arrays (mRNA expression correlation to protein expression by immunohistochemistry), to compare other publicly available prostate cancer datasets.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.